PAM Theragnostics

PAM Theragnostics is a preclinical-stage biotech company pioneering a vascular-centric approach to Alzheimer's disease (AD). The company's strategy focuses on the enzyme Peptidylglycine Alpha-Amidating Monooxygenase (PAM) as both a diagnostic biomarker and a therapeutic agent to strengthen the blood-brain barrier and slow disease progression. Founded by serial entrepreneur Dr. Andreas Bergmann, the company is funded by regional German/EU grants and is preparing for GMP production, with a First-In-Human trial targeted for 2027. Its unique angle involves learning from healthy centenarians to develop a preventive therapy.

Platform centered on the PAM (Peptidylglycine Alpha-Amidating Monooxygenase) enzyme, which activates protective vascular peptide hormones like adrenomedullin. It is being developed for both diagnostic (early detection via biomarker) and therapeutic (enzyme replacement) applications to target vascular dysfunction in Alzheimer's.

The Alzheimer's space is intensely competitive, dominated by large pharma and biotechs targeting amyloid, tau, and inflammation. PAM Theragnostics' vascular focus is a key differentiator, but it must compete for funding, clinical sites, and patient populations against well-resourced players with later-stage assets.